Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

Today, the American Kidney Fund (AKF) is convening its seventh annual national summit on Unknown Causes of Kidney Disease (UCKD) in Washington, D.C., bringing healthcare professionals, researchers, ...

Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation are on Capitol Hill with more than 80 advocates who are living with rare kidney diseases to urge elected officials to support ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Discover why Travere Therapeutics Inc's stock is sliding today, with insights into its recent patent news and leadership ...

Summary:The company released its 2026 interim report, reporting revenue of RMB 1.148 billion for the first half of 2026, up ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello ...

Travere Therapeutics, Inc.: Cours de bourse, graphiques, cotations, conseils boursiers, données financières, analyses et ...